Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer.
Paul RogowskiChristian TrappRieke von BestenbostelNina-Sophie Schmidt-HegemannRun ShiHarun IlhanAlexander KretschmerChristian StiefUte GanswindtClaus BelkaMinglun LiPublished in: Radiation oncology (London, England) (2021)
MDT is safe and offers high local control rates in bone oligometastases of prostate cancer. At 2 years after treatment, more than 2 out of 5 patients are progression-free. Trial registration Retrospectively registered.
Keyphrases
- prostate cancer
- end stage renal disease
- radical prostatectomy
- bone mineral density
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- soft tissue
- randomized controlled trial
- study protocol
- stem cells
- type diabetes
- bone regeneration
- adipose tissue
- mesenchymal stem cells
- phase ii
- insulin resistance
- smoking cessation
- glycemic control
- replacement therapy